Marco Pravetoni, Ph.D. - Publications

2008 University of Minnesota, Twin Cities, Minneapolis, MN 

44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Martinez S, Harris H, Chao T, Luba R, Pravetoni M, Comer SD, Jones JD. The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis. Expert Opinion On Investigational Drugs. 1-5. PMID 36863002 DOI: 10.1080/13543784.2023.2187286  0.335
2023 Triller G, Vlachou EP, Hashemi H, van Straaten M, Zeelen JP, Kelemen Y, Baehr C, Marker CL, Ruf S, Svirina A, Chandra M, Urban K, Gkeka A, Kruse S, Baumann A, ... ... Pravetoni M, et al. A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl. Cell Reports. 42: 112049. PMID 36719797 DOI: 10.1016/j.celrep.2023.112049  0.726
2022 Hamid FA, Marker CL, Raleigh MD, Khaimraj A, Winston S, Pentel PR, Pravetoni M. Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder. Vaccine. 40: 3244-3252. PMID 35469698 DOI: 10.1016/j.vaccine.2022.03.053  0.726
2021 Crouse B, Zhang L, Robinson C, Ban Y, Vigliaturo JR, Roy S, Pravetoni M. Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats. Human Vaccines & Immunotherapeutics. 1-10. PMID 34411500 DOI: 10.1080/21645515.2021.1954442  0.33
2020 Baehr CA, Huseby Kelcher A, Khaimraj A, Reed DE, Pandit SG, AuCoin D, Averick S, Pravetoni M. Monoclonal antibodies counteract opioid-induced behavioral and toxic effects in mice and rats. The Journal of Pharmacology and Experimental Therapeutics. PMID 32980813 DOI: 10.1124/jpet.120.000124  0.357
2020 Raleigh MD, Accetturo C, Pravetoni M. Combining a candidate vaccine for opioid use disorders with extended-release naltrexone increases protection against oxycodone-induced behavioral effects and toxicity. The Journal of Pharmacology and Experimental Therapeutics. PMID 32586850 DOI: 10.1124/Jpet.120.000014  0.474
2020 Gradinati V, Baruffaldi F, Abbaraju S, Laudenbach M, Amin R, Gilger B, Velagaleti P, Pravetoni M. Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity. Vaccine. PMID 32439214 DOI: 10.1016/J.Vaccine.2020.05.027  0.419
2020 Pravetoni M. Is the opioid use disorder epidemic impacting our immunological health? Brain, Behavior, and Immunity. PMID 32283290 DOI: 10.1016/J.Bbi.2020.04.022  0.318
2020 Lefevre EM, Pisansky MT, Toddes C, Baruffaldi F, Pravetoni M, Tian L, Kono TJY, Rothwell PE. Interruption of continuous opioid exposure exacerbates drug-evoked adaptations in the mesolimbic dopamine system. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32079024 DOI: 10.1038/S41386-020-0643-X  0.407
2020 Baehr C, Kelcher AH, Robinson C, Crouse B, Pravetoni M. Monoclonal Antibodies against Fentanyl and Fentanyl Analogs for Prevention of Opioid Overdose The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.05425  0.385
2020 Raleigh MD, King SJ, Saykao AT, Baruffaldi F, Gradinati V, Winston S, Pentel PR, Pravetoni M. Functional in vivo characteristics of antibodies generated by an oxycodone vaccine The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.03354  0.324
2019 Fulenwider HD, Nennig SE, Hafeez H, Price ME, Baruffaldi F, Pravetoni M, Cheng K, Rice KC, Manvich DF, Schank JR. Sex differences in oral oxycodone self-administration and stress-primed reinstatement in rats. Addiction Biology. e12822. PMID 31830773 DOI: 10.1111/Adb.12822  0.345
2019 Pravetoni M, Comer SD. Development of vaccines to treat opioid use disorders and reduce incidence of overdose. Neuropharmacology. PMID 31173759 DOI: 10.1016/J.Neuropharm.2019.06.001  0.409
2019 Baruffaldi F, Raleigh MD, King S, Roslawski M, Birnbaum A, Hassler C, Carroll FI, Runyon SP, Winston S, Pentel PR, Pravetoni M. Formulation and characterization of conjugate vaccines to reduce opioid use disorders suitable for pharmaceutical manufacturing and clinical evaluation. Molecular Pharmaceutics. PMID 31018096 DOI: 10.1021/Acs.Molpharmaceut.8B01296  0.348
2019 Robinson C, Baehr C, Schmiel SE, Accetturo C, Mueller DL, Pravetoni M. Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders. Human Vaccines & Immunotherapeutics. PMID 30625019 DOI: 10.1080/21645515.2018.1558697  0.451
2019 Baehr C, Pravetoni M. Vaccines to treat opioid use disorders and to reduce opioid overdoses. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 44: 217-218. PMID 30405185 DOI: 10.1038/S41386-018-0197-3  0.422
2018 Raleigh MD, Baruffaldi F, Peterson SJ, Le Naour M, Harmon TM, Vigliaturo JR, Pentel PR, Pravetoni M. Vaccination reduces fentanyl distribution to the brain and fentanyl-induced toxicity in mice and rats: a potential role for a prophylactic vaccine against fentanyl-induced overdose. The Journal of Pharmacology and Experimental Therapeutics. PMID 30409833 DOI: 10.1124/Jpet.118.253674  0.421
2018 Baruffaldi F, Huseby Kelcher A, Laudenbach M, Gradinati V, Limkar A, Roslawski M, Birnbaum A, Lees A, Hassler C, Runyon SP, Pravetoni M. Pre-clinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins. Molecular Pharmaceutics. PMID 30240216 DOI: 10.1021/Acs.Molpharmaceut.8B00592  0.432
2018 Laudenbach M, Baruffaldi F, Robinson C, Carter P, Seelig D, Baehr C, Pravetoni M. Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. Scientific Reports. 8: 5508. PMID 29615715 DOI: 10.1038/S41598-018-23777-6  0.438
2018 Raleigh MD, Laudenbach M, Baruffaldi F, Peterson SJ, Roslawski MJ, Birnbaum AK, Carroll FI, Runyon SP, Winston S, Pentel PR, Pravetoni M. Opioid dose- and route-dependent efficacy of oxycodone and heroin vaccines in rats. The Journal of Pharmacology and Experimental Therapeutics. PMID 29535156 DOI: 10.1124/Jpet.117.247049  0.373
2017 Raleigh MD, Peterson SJ, Laudenbach M, Baruffaldi F, Carroll FI, Comer SD, Navarro HA, Langston TL, Runyon SP, Winston S, Pravetoni M, Pentel PR. Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse. Plos One. 12: e0184876. PMID 29194445 DOI: 10.1371/Journal.Pone.0184876  0.463
2016 Pravetoni M. Biologics to treat substance use disorders: current status and new directions. Human Vaccines & Immunotherapeutics. 0. PMID 27441896 DOI: 10.1080/21645515.2016.1212785  0.336
2015 Laudenbach M, Tucker AM, Runyon SP, Carroll FI, Pravetoni M. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence. Vaccine. 33: 6332-9. PMID 26409811 DOI: 10.1016/J.Vaccine.2015.09.015  0.346
2015 Laudenbach M, Baruffaldi F, Vervacke JS, Distefano MD, Titcombe PJ, Mueller DL, Tubo NJ, Griffith TS, Pravetoni M. The Frequency of Naive and Early-Activated Hapten-Specific B Cell Subsets Dictates the Efficacy of a Therapeutic Vaccine against Prescription Opioid Abuse. Journal of Immunology (Baltimore, Md. : 1950). 194: 5926-36. PMID 25972483 DOI: 10.4049/Jimmunol.1500385  0.386
2015 Kotecki L, Hearing M, McCall NM, Marron Fernandez de Velasco E, Pravetoni M, Arora D, Victoria NC, Munoz MB, Xia Z, Slesinger PA, Weaver CD, Wickman K. GIRK Channels Modulate Opioid-Induced Motor Activity in a Cell Type- and Subunit-Dependent Manner. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 7131-42. PMID 25948263 DOI: 10.1523/Jneurosci.5051-14.2015  0.674
2015 Kotecki L, Hearing M, McCall NM, de Velasco EMF, Pravetoni M, Arora D, Victoria NC, Munoz MB, Xia Z, Slesinger PA, Weaver CD, Wickman K. GIRK channels modulate opioid-induced motor activity in a cell type- and subunit-dependent manner Journal of Neuroscience. 35: 7131-7142. DOI: 10.1523/JNEUROSCI.5051-14.2015  0.625
2014 Pravetoni M, Pentel PR, Potter DN, Chartoff EH, Tally L, LeSage MG. Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. Plos One. 9: e101807. PMID 25025380 DOI: 10.1371/Journal.Pone.0101807  0.366
2014 Pravetoni M, Vervacke JS, Distefano MD, Tucker AM, Laudenbach M, Pentel PR. Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats. Plos One. 9: e96547. PMID 24797666 DOI: 10.1371/Journal.Pone.0096547  0.417
2014 Taylor JJ, Laudenbach M, Tucker AM, Jenkins MK, Pravetoni M. Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse. Journal of Immunological Methods. 405: 74-86. PMID 24462800 DOI: 10.1016/J.Jim.2014.01.010  0.369
2014 LeSage MG, Raleigh MD, Pravetoni M, Tally L, Pentel P. Effects of a morphine-conjugate vaccine on heroin self-administration in rats Drug and Alcohol Dependence. 140: e119. DOI: 10.1016/J.Drugalcdep.2014.02.341  0.369
2013 Cornish KE, de Villiers SH, Pravetoni M, Pentel PR. Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions. Plos One. 8: e82557. PMID 24312662 DOI: 10.1371/Journal.Pone.0082557  0.323
2013 de Villiers SH, Cornish KE, Troska AJ, Pravetoni M, Pentel PR. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine. 31: 6185-93. PMID 24176492 DOI: 10.1016/J.Vaccine.2013.10.051  0.334
2013 Pravetoni M, Le Naour M, Tucker AM, Harmon TM, Hawley TM, Portoghese PS, Pentel PR. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. Journal of Medicinal Chemistry. 56: 915-23. PMID 23249238 DOI: 10.1021/Jm3013745  0.437
2013 Raleigh MD, Pravetoni M, Harris AC, Birnbaum AK, Pentel PR. Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. The Journal of Pharmacology and Experimental Therapeutics. 344: 397-406. PMID 23220743 DOI: 10.1124/Jpet.112.201194  0.437
2012 Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine. 31: 159-64. PMID 23123021 DOI: 10.1016/J.Vaccine.2012.10.069  0.314
2012 Pravetoni M, Raleigh MD, Le Naour M, Tucker AM, Harmon TM, Jones JM, Birnbaum AK, Portoghese PS, Pentel PR. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine. 30: 4617-24. PMID 22583811 DOI: 10.1016/J.Vaccine.2012.04.101  0.433
2012 Pravetoni M, Le Naour M, Harmon TM, Tucker AM, Portoghese PS, Pentel PR. An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. The Journal of Pharmacology and Experimental Therapeutics. 341: 225-32. PMID 22262924 DOI: 10.1124/Jpet.111.189506  0.438
2012 Pravetoni M, Keyler DE, Pidaparthi RR, Carroll FI, Runyon SP, Murtaugh MP, Earley CA, Pentel PR. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochemical Pharmacology. 83: 543-50. PMID 22100986 DOI: 10.1016/J.Bcp.2011.11.004  0.304
2010 Arora D, Haluk DM, Kourrich S, Pravetoni M, Fernández-Alacid L, Nicolau JC, Luján R, Wickman K. Altered neurotransmission in the mesolimbic reward system of Girk mice. Journal of Neurochemistry. 114: 1487-97. PMID 20557431 DOI: 10.1111/J.1471-4159.2010.06864.X  0.603
2010 Anderson GR, Cao Y, Davidson S, Truong HV, Pravetoni M, Thomas MJ, Wickman K, Giesler GJ, Martemyanov KA. R7BP complexes with RGS9-2 and RGS7 in the striatum differentially control motor learning and locomotor responses to cocaine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 1040-50. PMID 20043004 DOI: 10.1038/Npp.2009.212  0.62
2008 Perry CA, Pravetoni M, Teske JA, Aguado C, Erickson DJ, Medrano JF, Luján R, Kotz CM, Wickman K. Predisposition to late-onset obesity in GIRK4 knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 105: 8148-53. PMID 18523006 DOI: 10.1073/Pnas.0803261105  0.741
2008 Cruz HG, Berton F, Sollini M, Blanchet C, Pravetoni M, Wickman K, Lüscher C. Absence and rescue of morphine withdrawal in GIRK/Kir3 knock-out mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 4069-77. PMID 18400906 DOI: 10.1523/Jneurosci.0267-08.2008  0.659
2008 Pravetoni M, Wickman K. Behavioral characterization of mice lacking GIRK/Kir3 channel subunits. Genes, Brain, and Behavior. 7: 523-31. PMID 18194467 DOI: 10.1111/J.1601-183X.2008.00388.X  0.633
2007 Anderson GR, Lujan R, Semenov A, Pravetoni M, Posokhova EN, Song JH, Uversky V, Chen CK, Wickman K, Martemyanov KA. Expression and localization of RGS9-2/G 5/R7BP complex in vivo is set by dynamic control of its constitutive degradation by cellular cysteine proteases. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 14117-27. PMID 18094251 DOI: 10.1523/Jneurosci.3884-07.2007  0.575
Show low-probability matches.